| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.04B | 943.55M | 791.01M | 704.87M | 578.57M |
| Gross Profit | 704.77M | 627.82M | 541.24M | 489.98M | 426.80M |
| EBITDA | 380.67M | 310.36M | 318.55M | 272.62M | 236.37M |
| Net Income | 111.18M | -19.13M | -51.33M | -51.45M | -47.12M |
Balance Sheet | |||||
| Total Assets | 4.75B | 4.58B | 4.58B | 4.69B | 4.78B |
| Cash, Cash Equivalents and Short-Term Investments | 421.06M | 182.13M | 45.43M | 64.56M | 47.25M |
| Total Debt | 40.73M | 1.26B | 2.25B | 2.26B | 2.30B |
| Total Liabilities | 1.52B | 1.50B | 2.53B | 2.59B | 2.66B |
| Stockholders Equity | 3.22B | 3.08B | 2.05B | 2.11B | 2.12B |
Cash Flow | |||||
| Free Cash Flow | 284.52M | 142.50M | 29.94M | 85.20M | 91.86M |
| Operating Cash Flow | 307.81M | 169.77M | 51.46M | 102.63M | 106.41M |
| Investing Cash Flow | -23.29M | -27.27M | -61.52M | -17.43M | -444.33M |
| Financing Cash Flow | 16.49M | 16.65M | -17.15M | -67.06M | 331.50M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $6.73B | 29.06 | 25.96% | ― | 14.43% | 29.86% | |
78 Outperform | $8.27B | 15.45 | 22.32% | 1.42% | 7.40% | -14.45% | |
74 Outperform | $3.76B | 65.73 | 11.81% | ― | 44.34% | 45.96% | |
71 Outperform | $4.62B | 13.07 | 23.75% | 1.69% | -0.38% | 31.38% | |
70 Neutral | $11.29B | 31.59 | 10.21% | ― | 14.26% | -15.49% | |
68 Neutral | $6.17B | 52.99 | 3.54% | ― | 14.75% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
On October 1, 2025, Waystar Holding Corp. completed its acquisition of Iodine Software, enhancing its AI-powered healthcare payment platform by integrating Iodine’s clinical and financial intelligence. This acquisition expands Waystar’s market by over 15% and is expected to improve its financial profile through increased gross margin and revenue growth. The merger, valued at approximately $458.6 million in cash and stock, also led to the appointment of Lauren Young to Waystar’s board, reflecting the strategic importance of the acquisition in strengthening Waystar’s position in the healthcare industry.
On September 10, 2025, Waystar Holding Corp. announced an underwriting agreement with J.P. Morgan Securities LLC for an offering of 18,000,000 shares of its common stock. The company will not receive any proceeds from this offering, which is expected to close on September 12, 2025, indicating a strategic move that may impact stakeholders by altering the distribution of shares without affecting the company’s immediate financial position.